Paracrine Mediators of Endometrial Matrix Metalloproteinase Expression
- 1 March 2002
- journal article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 955 (1) , 139-146
- https://doi.org/10.1111/j.1749-6632.2002.tb02774.x
Abstract
Abstract: The endometrial lining of the human uterus is a highly specialized, steroid‐sensitive tissue. Throughout the reproductive years, the endometrium undergoes dramatic cycles of growth, differentiation, and breakdown under the influence of ovarian steroids. In response to changes in steroid exposure throughout the menstrual cycle, the endometrium produces an array of bioactive growth factors and other cytokines that are critical components of paracrine communication. For example, cell‐cell communication via paracrine factors directs the expression of matrix metalloproteinases (MMPs), enzymes that mediate tissue remodeling during the menstrual cycle. The disease endometriosis is thought to occur as a consequence of retrograde menstruation, and MMPs appear to contribute to the establishment and progression of ectopic endometrial growth in the peritoneal cavity. Although the risk for developing endometriosis is linked to a woman's steroid exposure, locally produced paracrine factors can modify steroid action on multiple gene targets, including the MMPs. Estrogen‐associated growth factors as well as inflammatory cytokines are potent stimulators of MMP expression and may contribute to the ability of endometrial fragments to invade the peritoneal surface and establish ectopic sites of growth. In contrast, paracrine factors associated with progesterone action during early pregnancy inhibit MMP expression and prevent ectopic endometrial growth in an experimental model. For example, locally produced retinoic acid and transforming growth factor‐β (TGF‐β) act in concert with progesterone to suppress MMPs, while enhancing expression of MMP inhibitors (TIMPs) during endometrial differentiation. Targeting pregnancy‐associated factors that inhibit endometrial‐specific MMP expression and action may enhance the effectiveness of progestin‐related treatments for endometriosis.Keywords
This publication has 27 references indexed in Scilit:
- Establishment of Experimental Endometriosis by Eutopic or Ectopic Endometrial Tissue Acquired from Women with Endometriosis Cannot be Prevented by Progesterone TreatmentsFertility and Sterility, 2000
- Progesterone Exposure Prevents Matrix Metalloproteinase-3 (MMP-3) Stimulation by Interleukin-1 in Human Endometrial Stromal CellsJournal of Clinical Endocrinology & Metabolism, 2000
- Suppression of matrix metalloproteinases inhibits establishment of ectopic lesions by human endometrium in nude mice.Journal of Clinical Investigation, 1997
- The AP-1 site and MMP gene regulation: What is all the fuss about?Matrix Biology, 1997
- Steroid and Growth Factor Regulation of Matrix Metalloproteinase Expression and EndometriosisSeminars in Reproductive Medicine, 1996
- Interleukin-6 secretion in vitro is up-regulated in ectopic and eutopic endometrial stromal cells from women with endometriosisJournal of Clinical Endocrinology & Metabolism, 1996
- Patterns of matrix metalloproteinase expression in cycling endometrium imply differential functions and regulation by steroid hormones.Journal of Clinical Investigation, 1994
- Cytokine regulation of metalloproteinase gene expressionJournal of Cellular Biochemistry, 1993
- Endometriosis: its association with retrograde menstruation, dysmenorrhoea and tubal pathologyBJOG: An International Journal of Obstetrics and Gynaecology, 1986
- TISSUE CHANGES FOLLOWING DEPRIVATION OF FAT-SOLUBLE A VITAMINThe Journal of Experimental Medicine, 1925